Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "neutral" rating reissued by research analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They presently have a $10.00 price objective on the stock, down from their previous price objective of $14.00. Wedbush's target price would indicate a potential downside of 1.96% from the company's current price.

A number of other equities analysts have also commented on the company. Robert W. Baird dropped their price objective on Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Oppenheimer dropped their price target on Intellia Therapeutics from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Monday, November 11th. The Goldman Sachs Group reduced their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Canaccord Genuity Group restated a "buy" rating and issued a $90.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $52.81.

Intellia Therapeutics Trading Down 15.1 %

Intellia Therapeutics stock traded down $1.82 during trading hours on Friday, reaching $10.20. 7,215,488 shares of the company were exchanged, compared to its average volume of 3,277,925. Intellia Therapeutics has a 12 month low of $9.93 and a 12 month high of $34.87. The stock has a 50-day moving average of $13.87 and a 200 day moving average of $19.10. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -1.87 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics's quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.38) earnings per share. As a group, research analysts forecast that Intellia Therapeutics will post -5.12 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 28,735 shares of company stock worth $349,909 over the last three months. Company insiders own 3.20% of the company's stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its holdings in shares of Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock worth $105,700,000 after purchasing an additional 780,754 shares during the last quarter. Patient Square Capital LP bought a new stake in Intellia Therapeutics during the 3rd quarter worth about $2,642,000. Dimensional Fund Advisors LP grew its holdings in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after acquiring an additional 98,865 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Intellia Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock worth $17,006,000 after acquiring an additional 37,714 shares during the last quarter. Finally, Verition Fund Management LLC raised its stake in shares of Intellia Therapeutics by 116.3% in the third quarter. Verition Fund Management LLC now owns 94,426 shares of the company's stock worth $1,940,000 after acquiring an additional 50,763 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.